secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sanara MedTech Inc. (SMTI)
CIK:        0000714256
Form:       8-K
Filed at:   2026-05-11T21:21:56+00:00
Accession:  0001493152-26-022291
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sanara MedTech Q1 net revenue up 19% to $27.8M; GAAP EPS $0.04 vs ($0.07) loss
------------------------------------------------------------------------------

- Net income from continuing ops of $0.4M ($0.04 diluted EPS) vs loss of $0.6M ($0.07) YoY.
- Adjusted EBITDA $4.3M (+58% YoY); gross margin improved to 93% from 92%.
- Soft tissue repair revenue rose 21% to $24.9M; bone fusion revenue essentially flat at $2.9M.
- Q2 2026 revenue guidance $28.5M-$29.5M (10-14% growth); full-year 2026 reaffirmed at $116M-$121M.
- Sales team expanded to 43 reps; products contracted at >4,000 U.S. facilities; cash $13.6M, debt $46.2M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/714256/000149315226022291/0001493152-26-022291-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/714256/000149315226022291/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-022291

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer